Teladoc (TDOC) Outperforms Broader Market: What You Need to Know

Company Overview - Teladoc's stock closed at $7.40, reflecting a +1.79% change from the previous day, outperforming the S&P 500's daily gain of 0.09% [1] - Over the past month, Teladoc's stock has increased by 2.25%, slightly above the Medical sector's gain of 2.17%, but below the S&P 500's gain of 7.21% [1] Earnings Forecast - The upcoming earnings release is anticipated, with an expected EPS of -$0.23, indicating a 17.86% growth compared to the same quarter last year [2] - Revenue is forecasted to be $621.92 million, representing a 3.19% decline from the corresponding quarter of the previous year [2] Full Year Projections - For the full year, earnings are projected at -$1.17 per share and revenue at $2.51 billion, showing changes of +80.07% and -2.15% respectively from the previous year [3] Analyst Forecast Revisions - Recent revisions to analyst forecasts for Teladoc are important, as they reflect changes in short-term business dynamics [4] - Positive revisions indicate analysts' confidence in the company's performance and profit potential [4] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a history of outperforming, with 1 stocks averaging a +25% annual gain since 1988 [6] - Over the last 30 days, the Zacks Consensus EPS estimate for Teladoc has increased by 8.56%, and the company currently holds a Zacks Rank of 3 (Hold) [6] Industry Context - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 68, placing it in the top 28% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]